心肌乏氧显像及其临床应用

张弘; 蒋宁一

心肌乏氧显像及其临床应用

张弘 , 蒋宁一

文章导航 > 国际放射医学核医学杂志 > 2004, 28 > 3: (113-117)

引用本文:

Citation:

心肌乏氧显像及其临床应用

张弘,
蒋宁一

510120 广州, 中山大学附属第二医院核医学科
中图分类号: R817.4

Myocardial hypoxia imaging and clinical application

Department of Nuclear Medicine, The Second Affiliate Hospital of Sun Yat-sun University, Guangzhou 510120, China
CLC number: R817.4

摘要: 心肌乏氧显像是通过评价心肌氧供与氧耗平衡而提供检测缺血但存活心肌的一种非侵入性检查方法,而且是评价血管生成及心肌病的发生和发展的有用指标。动物实验和已有的临床研究表明,¹⁸F标记的硝基咪唑类化合物、有广泛应用前景的⁹⁹Tc^m标记的咪唑类化合物以及其他新的乏氧显像剂已用于评价缺血存活心肌。广泛的临床应用有待于进一步实验及临床研究。
- 心肌乏氧显像 /
- 乏氧显像剂 /
- 临床应用
Abstract: Myocardial hypoxia imagings provide noninvasive approaches for the detection of myocardial ischemia, dedication of the potential role of hypoxia in development of angiogenesis and cardiomyopathy by the detection of balance of flow and oxygen consumption. Animal experiments and clinical trials show fluoromisonidazole and technetium-99m labeled nitroimidazoles and novel class hypoxia imaging markers have been developed for imaging of regional myocardial ischemia. The true clinical applications rely on future experimental and clinical studies.
- myocardium /
- hypoxia imaging /
- clinical application
本作品遵循Signature-Non-Commercial Use 4.0 International (CC BY-NC 4.0)协议

[1]	Takahashi N, Fujibayashi Y, Yonekura Y, et al. Copper62 ATSM as a hypoxic tissue tracer in myocardial ischemia[J]. Ann Nucl Med, 2001, 15:293-296.
[2]	Koch CJ and Evans SM. Non-invasive PET and SPECT imag-ing of tissue hypoxia using isotopically labeled 2-nitroimi-dazoles[J]. Adv Exp Med Biol, 2003, 510:285-292.
[3]	Imahashi K, Morishita K, Kusuoka H, et al. Kinetics of a pu-tative hypoxic tracer, 99mTc-HL91, in normoxic, hypoxic,is-chemic, and stunned myocardium[J]. J Nucl Med,2000, 41:1102-1107.
[4]	Kaneta T, Takai Y, Kagaya Y, et al. Imaging of ischemic but viable myocardium using a new F-labeled 2-nitroimidazole analog, F-FRP170[J]. J Nucl Med, 2002, 43:109-116.
[5]	Yue X and Tomanek RJ. Effects of VEGF (165)and VEGF (121) on vasculogenesis and angiogenesis in cultured embryonic quail hearts[J]. Am J Physiol Heart Circ Physiol,2001, 280:2240-2247.
[6]	Tham E, Wang J, Piehl F, et al. Up regulation of VEGF-A without angiogenesis in a mouse model of dilated cardiomyopathy caused by mitochondrial dysfunction[J]. J Histochem Cytochem, 2002, 50:935-944.
[7]	El-Omar MM, Lord R, Draper NJ, et al. Role of nitric oxide in post hypoxic contractile dysfunction of diabetic cardiomyopathy[J]. Eur J Heart Fail, 2003, 5:229-239.
[8]	Patt M, Sorger D, Scheunemann M, Adduct of 2-[¹⁸F] FDG and 2-nitroimidazole as a putative radiotracer for the detection of hypoxia with PET:synthesis, in vitro-and in vivo-characterization[J]. Appl Radiat Isot, 2002, 57:705-712.
[9]	Josse O, Labar D, Georges B, et al. Synthesis-of[¹⁸F] la beled EF3[2-(2-nitroimidazol-1-yl)-N-(3, 3, 3-trifluoropropyl)-acetamide], a marker for PET detection of hypoxia[J]. Bioorg Med Chem, 2001, 9:665-675.
[10]	Koch CJ and Evans SM. Non-invasive PET and SPECT imaging of tissue hypoxia using isotopically labeled 2-nitroimidazoles[J]. Adv Exp Med Biol, 2003, 510:285-292.
[11]	Hoffend J, Linke G, Mohammed A, et al. 99mTcO (BATNI), a novel nitroimidazole tracer:in vivo uptake studies in alchemic myocardium[J].Eur J Nucl Med Mol Imag,2003, 30:494-501.
[12]	Johnson LL, Schofield L, Donahay T, et al. Myocardial uptake of a (99m)Tc-nitroheterocycle in a swine model of occlusion and reperfusion[J]. J Nucl Med, 2000, 41:1237-1243.
[13]	Su ZF, Ballinger JR, Rauth AM, et al. A novel aminedioxide chelator for technetium-99m:synthesis and evaluation of 2-nitroimidazole-containing analogues as markers for hypoxic cells[J]. Bioconjug Chem, 2000, 11:652-663.
[14]	Ng C, Sinusas A, Zaret B, et al. Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS181321), as a tracer for myocardial hypoxia[J]. Circulation, 1995, 92:1261-1268.
[15]	Shi CQ, Sinusas AJ, Dione DP, et al. Technetium-99m-nitroimidazole (BMS181321):A positive imaging agent for detecting myocardial ischemia[J]. J Nucl Med, 1995, 36:1078-1086.
[16]	Melo T, Duncan J, Ballinger JR, et al. BRU59-21, a second-generation 99mTc-labeled 2-nitroimidazole for imaging hypoxia in rumors[J]. J Nucl Med, 2000, 41:169-176.
[17]	Suzuki T, Nakamura K, Kawase T, et al. Biodistribution of hypoxic marker, 99mTc-HL91[J]. Kaku Igaku, 2001, 38:333-341.
[18]	Okada RD, Johnson G, Nguyen KN, et al. HL-91-techentium-99m:a new marker of viability in ischemic myocardium[J]. J Nucl Cardiol, 1999, 6:306-315.
[19]	Fujibayashi Y, Cutler CS, Anderson CJ, et al. Comparative studies of Cu-64-ATSM and C-11-acetate in a acute myocardial infarction model:ex vivo imaging of hypoxia in rats[J]. Nucl Med Biol, 1999, 26:117-121.
[20]	Watanabe Y, Kusuoka H, Fukuchi K, et al. Contribution of hypoxia to the development of cardiomyopathy in hamsters[J]. Cardiovasc Res. 1997. 35:217-222.

[1]	汪会 , 徐慧琴 . 肿瘤乏氧显像剂的研究进展. 国际放射医学核医学杂志, 2012, 36(6): 366-370. doi: 10.3760/cma.j.issn.1673-4114.2012.06.011
[2]	蒋宁一 , 吕斌 , 管昌田 . 韧致辐射显像的进展. 国际放射医学核医学杂志, 1996, 20(5): 199-201.
[3]	管昌田 . 放射性碘化MIBG在肾上腺素能肿瘤定位诊断和治疗中的应用. 国际放射医学核医学杂志, 1996, 20(5): 193-199.
[4]	朱霖 , 刘秀杰 . 乏氧组织显像剂及其应用. 国际放射医学核医学杂志, 1997, 21(4): 150-154.
[5]	陈跃 , 莫廷树 , 匡安仁 . 肿瘤乏氧组织显像剂研究进展. 国际放射医学核医学杂志, 1999, 23(6): 257-260.
[6]	许飞 , 刘建军 , 黄钢 , 宋少莉 . PET乏氧显像在预测肿瘤乏氧及指导临床治疗中的应用进展. 国际放射医学核医学杂志, 2016, 40(1): 35-43. doi: 10.3760/cma.j.issn.1673-4114.2016.01.008
[7]	李莉 , 李美佳 , 郑妙 . 乏氧组织显像剂研究最新进展. 国际放射医学核医学杂志, 1999, 23(3): 134-139.
[8]	杜雪梅 , 张延军 . 核素乏氧显像在肿瘤放射治疗中的应用. 国际放射医学核医学杂志, 2008, 32(2): 96-98.
[9]	苏新辉 , 吴华 . ^99mTc-HL91乏氧显像探测肿瘤乏氧状态的研究进展. 国际放射医学核医学杂志, 2006, 30(4): 220-222.
[10]	林伟 , 邬恒夫 , 武兆忠 , 邓力平 , 刘影 , 吴长伟 , 丁志辉 . ^99mTc-HL91显像在缺血陛脑血管病中脑乏氧组织的应用研究. 国际放射医学核医学杂志, 2008, 32(3): 165-166,174.

点击查看大图

计量

文章访问数: 1109
HTML全文浏览量: 123
PDF下载量: 3

心肌乏氧显像及其临床应用

张弘
蒋宁一

510120 广州, 中山大学附属第二医院核医学科

收稿日期: 2003-09-22

关键词:

摘要: 心肌乏氧显像是通过评价心肌氧供与氧耗平衡而提供检测缺血但存活心肌的一种非侵入性检查方法,而且是评价血管生成及心肌病的发生和发展的有用指标。动物实验和已有的临床研究表明,¹⁸F标记的硝基咪唑类化合物、有广泛应用前景的⁹⁹Tc^m标记的咪唑类化合物以及其他新的乏氧显像剂已用于评价缺血存活心肌。广泛的临床应用有待于进一步实验及临床研究。